Afya Got Some Regulatory Respite But The Education Quality Risk Remains

Afya Limited reported 2Q26 revenue up 6% YoY, described as barely above inflation, alongside margin contraction and slower student growth. Tuition price increases are now only keeping pace with inflation, signaling weakened pricing power versus the prior premium-seat thesis. Regulatory risk tied to ENAMED exam results persists, though a temporary injunction has lifted some restrictions—keeping seat capacity and brand reputation uncertainty in focus.

Analysis

AFYA is moving from a scarcity/price-leverage story to a regulated-capacity story, and that usually deserves a lower multiple even before the P&L fully shows it. The key mechanism is not the 6% top-line print; it is that tuition now tracking inflation implies the company is losing its ability to expand ARPU faster than input costs, so incremental margins should compress if management leans on marketing or discounts to defend seats.

The near-term overhang is binary but not cleanly resolved by the temporary injunction. In the next 1-3 months, the market will trade seat-allocation and exam-result headlines as a proxy for whether Afya can preserve enrollment economics; if the regulatory process tightens, the company may need to spend more to maintain brand perception, which hurts EBITDA more than revenue. Over 6-18 months, the bigger risk is structural: if the brand loses its premium positioning, AFYA becomes just another Brazilian education asset with lower ROIC and less defensible cash flow.

Contrarian view: consensus may be underestimating how little the injunction solves if exam outcomes remain a gatekeeper for growth. The flip side is that the stock could rebound sharply if regulatory clarity arrives faster than expected, because positioning likely remains fragile and any confirmation that seat capacity is protected would force a repricing. Falsifier: a reacceleration in tuition above CPI or a sustained pickup in student growth over the next two reporting periods would argue the pricing-power thesis is wrong.

Key Decisions for Investors

• Short AFYA into strength over the next 2-4 weeks; the setup is a multiple-risk trade, not a growth disappointment trade. Favor a 3-6 month horizon because the catalyst path is regulatory, not quarterly.
• If options liquidity is sufficient, use an AFYA put spread rather than outright puts to express downside while limiting premium bleed; target the next regulatory/news window over 1-3 months.
• Use AFYA as a relative-value short versus less regulation-sensitive Brazilian education exposure only if you can source a cleaner hedge; the point is to isolate seat-capacity/regulatory risk from broad Brazil beta.
• Set a hard stop/watch item: cover if management shows tuition growth above inflation by the next two reports or if regulatory actions permanently restore seat visibility; those would invalidate the margin-compression thesis.
• Avoid chasing the first rebound after injunction headlines; wait for either confirmed enrollment weakness or a fresh regulatory adverse event before adding size.